2023 Horizon Europe call to support the EU Cancer Mission
stephanie.dhont2023-03-22T09:25:01+01:00Apply for the 2023 HorizonEU call under the EU Cancer [...]
March 2023
Call for projects – PANCREAS 2023
stephanie.dhont2023-03-17T09:12:42+01:00As a continuation of its scientific strategy initiated in 2022 [...]
February 2023
Launch of the 12th Bristol Myers Squibb Foundation call for proposals for research in immuno-oncology
stephanie.dhont2023-02-15T13:21:29+01:00The Bristol Myers Squibb Foundation announces the launch of its [...]
BIPER THERAPEUTICS RAISES €1.25 MILLION
stephanie.dhont2023-02-14T12:07:14+01:00BiPer Therapeutics, awarded during OUI (Oncology Upward Investment) 2021 edition [...]
Partnership MATWIN and European Health Investor Network
stephanie.dhont2023-02-02T10:48:11+01:00MATWIN and the European Health Investor Network announce their new [...]
Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma
stephanie.dhont2023-02-01T14:21:34+01:00Genoscience Pharma, supported by MATWIN in 2021, receives FDA orphan [...]
January 2023
First US leukemia patient dosed with investigational SMART101 cell therapy
stephanie.dhont2023-01-23T15:07:55+01:00Smart Immune announced today that the first adult leukemia patient [...]
Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”
stephanie.dhont2023-01-19T15:25:45+01:00Brenus Pharma, a biotech company specialized in the development of [...]
Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial
stephanie.dhont2023-01-18T10:55:54+01:00Genoscience Pharma announces launch of phase 2b clinical trial of [...]
EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
stephanie.dhont2023-01-17T12:26:28+01:00EverImmune supported by MATWIN in 2022 and interviewed by the [...]